QUIBIM team is proud to announce that the beneficiaries of the European Commission SME Instrument Phase 2 have been recently published, and our project has been awarded in the Open Disruptive Innovation (ODI) topic.
QUIBIM’s project “QUIBIM Precision” has been granted with 1.25M€ for the scaling and development of the company business plan through our cloud platform QUIBIM Precision®. This funding will boost and accelerate the strategic plan of the company, bringing new disruptive solutions to our platform, including dedicated High Performance Computing resources for our Machine Learning processes, incorporating new visual analytics tools and helping validate new imaging biomarkers that have been recently developed.
QUIBIM Precision® is an innovative imaging biomarker analysis platform in the cloud allowing for:
- Automated analysis of imaging biomarkers (results are ready just within minutes) with the best accuracy and reproducibility.
- Medically certified: QUIBIM is medically valid to scientifically support decision making.
- Open to any physicians: Optimized User Interface (UI), user experience (UX) and imaging analysis functionalities.
- Cost-effective: QUIBIM helps reduce costs of medical testing and misdiagnosis.
Our technology based on machine learning and image processing algorithms scouts the image and compares it to similar images in our database with known ground-truth diagnosis, based on patterns not obvious to a human eye.
QUIBIM is a biotechnology company dedicated to advanced medical image analysis. It was one of the start-ups selected in the 3rd edition of the acceleration program “LANZADERA” and it’s a spin-off company of the Medical Research Institute Hospital La Fe. Recently the company closed an investment round to boost its growth, including Tech Transfer UPV, AYCE Capital, and BioInfoGate, as well as some company promoters . QUIBIM’s business model is based on the extraction of quantitative information from radiological and nuclear medicine imaging using original and advanced computational processing techniques.
In 2016, QUIBIM was also selected as one of the disruptive companies by the EU and granted with the first round of Horizon 2020 SME Instrument Phase I Program 2016 under the call: “SMEInst-01- 2016-2017: Open Disruptive Innovation Scheme”
SME instrument – Horizon 2020 call
The SME Instrument is divided into 3 phases covering different stages of the innovation cycle. Phase 1 aims to cover the assessment of technical feasibility and market potential of new ideas. The project will be supported by an investment of 50,000€ and the typical duration should be no longer than 6 months.
Phase 2 aims to cover R&D activities with a particular focus on demonstration activities (testing, prototype, scale-up studies, design, piloting innovative processes, products and services, validation, performance verification etc.) and market replication encouraging the involvement of end users or potential clients. Project funding should amount to no more than 2,500,000€ and the typical duration of this phase should range from 12 to 24 months.